China’s HD Biosciences Completes Series A Financing; Led By Lilly, Pfizer And Morningside
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - HD Biosciences has completed its first round of external financing, led by Morningside Group and Lilly Asian Ventures and syndicated with Pfizer Venture Investments, the company announced Aug. 7
You may also be interested in...
Pfizer Increasing Size of China R&D Center, Expanding Virtual Research Network Through Alliances With Chinese Scientists, WuXi PharmaTech
BEIJING - Pfizer is set to ramp up its research and development center in Shanghai and to integrate more Chinese scientists into its worldwide virtual R&D network, including a new research deal with Wuxi PharmaTech, according to senior Pfizer executives in Shanghai and Hong Kong
Pfizer Increasing Size of China R&D Center, Expanding Virtual Research Network Through Alliances With Chinese Scientists, WuXi PharmaTech
BEIJING - Pfizer is set to ramp up its research and development center in Shanghai and to integrate more Chinese scientists into its worldwide virtual R&D network, including a new research deal with Wuxi PharmaTech, according to senior Pfizer executives in Shanghai and Hong Kong
Chinese CRO Alliance Sets Eyes On Europe
SHANGHAI - U.K.-based NovaSecta joined Sundia Meditech and HD Biosciences in China's first contract research organization alliance, the three companies announced Feb. 18